Carlo Ferrari

TL;DR: Present data suggest that several patients with hypothyroidism consequent to hypothalamic-pituitary diseases secrete a material which is immunologically similar to pituitary standard TSH and responds to stimulatory and suppressive agents in a manner similar to normal TSH but has low or absent biological activity.

TL;DR: The data from this study in combination with previous reports can exclude a congenital malformation risk greater than 10% associated with pregnancy exposure to cabergoline.

TL;DR: Out of 21 patients with active acromegaly, 12 increased plasma GH concentration after TRH injection (200 μg iv), and it is suggested that in some functioning pituitary tumors the activity of TRH in promoting GH release may be attributed to an alteration of the cellular membrane.

TL;DR: It is indicated that cabergoline has potent and prolonged dopaminergic activity and may prove suitable for once weekly treatment of hyperprolactinemic patients.

TL;DR: Following cabergoline discontinuation, prolactin levels increased slowly, being still markedly lower than pretreatment values after three months; 10 patients out of 32 had persistently normal prolACTin levels during one year of follow-up.